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Introduction
Lentigo Maligna (LM) typically presents at sun-exposed sites in elderly patients as an asymmetric, 
slow-growing, irregularly pigmented macule with an irregular indented border. With changes in sun 
exposure behaviour LM is becoming more prevalent in middle-aged and younger adults.
1
The risk of melanoma developing in LM increases with duration of the disease and therefore age,
2 
and is difﬁ  cult to quantify, estimates range from 2.2%
2 to 50%
3 over a lifetime, once invasive disease 
is established, the tumour carries the same prognosis as other types of cutaneous malignant melanoma 
as deﬁ  ned by Breslow thickness and presence of ulceration.
LM presents a difﬁ  cult clinical problem and generally there is little consensus on the optimum form 
of management. The recommended guidelines for treatment of LM are surgical excision with excision 
margins into clinically normal skin of 2–5 mm.
4,5 Others have suggested that up to 20% of cases of LM 
would require margins greater than this.
6 However, lesions are commonly large and located on 
cosmetically important head and neck sites. Excision may result in a poor cosmetic outcome and it is 
difﬁ  cult to justify this approach when the risk of malignant transformation may well be low. Amelanotic 
lentigo maligna also remains a signiﬁ  cant problem and inevitably results in incomplete excision since 
clinical identiﬁ  cation of disease extent is impossible.
7
Non-surgical treatment options are used in 50% of U.K. patients over the age of 70, these include 
radiotherapy, retinoids,
8 5-FU and azelaic acid. Cryotherapy, once popular, has fallen from favour 
because of reports of invasive melanoma occurring after cryotherapy ablation.
9 Commonly a “watch 
and wait” policy is adopted.
Imiquimod (Aldara, Meda Pharmaceuticals Ltd) is a topical immune response modiﬁ  er. The drug 
causes an increase in interferon locally and therefore may have a place in the management of superﬁ  cial 
interferon sensitive malignancy. There are several reports of its use to treat lentigo maligna.
10–12 We 
describe our experience with the use of imiquimod in a group of patients with LM on the head and neck 
where surgery was not an option.
Patients and Methods
8 patients with histologically conﬁ  rmed recurrent or difﬁ  cult to treat LM of the head and neck were 
treated. All had declined surgery. Four LMs had recurred after previous surgery, one recurred after 
cryotherapy (Table 1) and three others had previously untreated large lesions with indistinct margins.
Patients were instructed to apply the cream to the pigmented area and to a minimum 1 cm margin 
around the pigmented area once a day, ﬁ  ve days per week for a minimum of 6 weeks. Patients were 
told to expect a brisk inﬂ  ammatory reaction to occur at the treated sites and to continue imiquimod 
despite this. At the end of the 6-week period they were reviewed.
Inﬂ  ammatory response was graded as no reaction, minimal reaction, brisk reaction, very brisk reaction 
and was carried out by the same clinician. In some cases, where the response appeared to be minimal 
or there was concern that the patient had not used the cream appropriately, a further course was prescribed. 
At the end of therapy if pigmentation persisted this area was biopsied. Clinical photographs were taken 
before and after imiquimod treatment.552
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Results
The clinical and demographic data for all 8 patients 
is given in Table 1.
8 patients (average age 67.25 years) with a total 
of 8 lesions of LM were treated with imiquimod. 
Patients were followed up until their most recent 
appointment, which for those responsive to treat-
ment is an average of 34.2 months (10, 63).
Patient Response to Imiquimod
In 3 patients (patients 1,2,8) the initial inﬂ  amma-
tory response was minimal. Five patients (patients 
3,4,5,6,7) developed a rapid and brisk response to 
imiquimod on ﬁ  rst course application. The area 
became red, weeping and ﬁ  nally crusted over.
Patient 1 cleared the LM from the tip of the nose 
but developed pigmentation on the upper lip at a 
site where imiquimod had not been applied. Ini-
tially she had applied the cream very sparingly to 
a small area on the tip of the nose. There had been 
a minimal inﬂ  ammatory response. She was happy 
with the outcome and declined a second course of 
treatment. Patient 2, despite apparent correct appli-
cation over 2 courses, did not develop any inﬂ  am-
matory response. It was thought likely that she had 
not used sufﬁ  cient cream because of her concerns 
about the described inﬂ  ammatory reaction. The 
pigmented area reduced but did not resolve. Biopsy 
confirmed the presence of lentigo maligna. 
Patient 8 applied imiquimod for 6 weeks but there 
was no inﬂ  ammatory reaction and no change in the 
appearance of the LM. It was subsequently discov-
ered that he had been using a sunscreen and skin 
moisturiser when he had used the imiquimod. He 
stopped using the skin care products and reapplied 
the imiquimod, once a day, 5 days per week for 
6 weeks; there was a very brisk response and the 
pigment resolved.
All of the six patients (patients 3,4,5,6,7,8) who 
developed an inﬂ  ammatory response had clinical 
resolution of their LM. Patients with a clinical 
response were followed up for an average of 34.2 
months without clinical recurrence. Patients 1 and 2 
were deemed treatment failures, with the develop-
ment of biopsy proven recurrence or incomplete 
clearance. Photography shows the brisk inﬂ  amma-
tory reaction and clinical resolution of the LM in 
patients. In patient 3 (picture 3) there was residual 
pigmentation for 2 months and this area was biop-
sied. The biopsy showed pigment laden macro-
phages and no evidence of recurrent LM. This 
pigmentation resolved completely 4 months 
later.
Comments
We have shown that in 6 out of 8 patients with 
lentigo maligna treated with imiquimod, the 
tumour resolved clinically with no evidence of 
recurrence after a mean follow up of 34.2 months. 
A brisk inﬂ  ammatory reaction was a prerequisite 
of therapeutic response.
Imiquimod is a member of the imidazoquino-
lone drugs, a group of drugs that are unique in 
having both the properties of immune response 
modiﬁ  cation and stimulation. It acts as an immune 
modulator by binding to Toll-Like Recep-
tor 7 (TLR-7) present on macrophages, monocytes 
and dendrites cells. Activation of these cells leads 
to the release of proinﬂ  ammatory mediators that 
drive the activation of the TH-1 pathway and 
upregulation of NK-cell activity. Topical applica-
tion has also been shown to enhance maturation 
and migration of Langerhan’s cells and provide a 
more speciﬁ  c immune response.
13 It has also been 
shown that imiquimod can induce apoptosis of 
different call lines by FasR induction, downregula-
tion of Bcl-2, an antiapoptotic molecule, and acti-
vation of caspases 3 and 9.
14 This may explain why 
it has been effective in the treatment of malignant 
proliferations.
Our study shows that 75% patients with LM 
who developed an inflammatory response to 
imiquimod were clinicall clear of their LM during 
the period of observation. Several studies
11,18 have 
shown similar beneﬁ  ts, Naylor et al.
19 demon-
strated clinical and histological resolution of 93% 
of 28 LM 4 weeks after a 12 week treatment regi-
men with 80% having no evidence of relapse after 
a year.
Our observations support the concept that an 
inﬂ  ammatory response is an essential component 
of imiquimod treatment success. Patients and phy-
sicians should be prepared for the potentially 
severe inﬂ  ammatory response and know how to 
manage this. Photographs of typical reactions are 
useful for informing potential patients. It is also 
important to be aware that there will be inﬂ  amma-
tion of any co-existing actinic keratoses. In our 
study all patients managed to complete the course 
of treatment although some required a rest period 
because of tissue reaction. It is possible that an 
altered dose regimen may reduce the impact of the 554
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inflammatory response without changing the 
therapeutic effect.
15
The time frame of treatment in most our patients 
was only for 6 weeks, 1 patient had two 6 week 
treatment courses. Other studies have used 
treatment times of up to 12 weeks. It seems that it 
is the inﬂ  ammatory response that is important and 
the time taken to achieve that in most cases was a 
6 weeks course.
Despite concerns that the use of imiquimod may 
promote tumourigeneseis and increase the rate of 
transformation to LMM only one case has been 
reported.
17 Systemic side effects can also occur 
with a ﬂ  u like illness, shooting pains and general 
malaise, and although this was not directly reported 
in this group these symptoms have been seen in 
other patients using imiquimod by the observer.
20
Although based on only one case we have dem-
onstrated that emollients and other skincare prod-
ucts may act as a barrier preventing imiquimod 
absorption or cause its degradation. It may be use-
ful top warn patients not to use any other skin care 
product during the treatment phase.
We did not biopsy clinically cleared LM, only 
areas of suspicion. A pilot study
16 showed that 5 out 
of 6 patients treated with LM had complete or 
almost complete clinical clearance despite 
histological persistence. If this is correct then a 
post-operative sample biopsy could easily miss 
patchy persistent disease and only complete 
excision of the previously affected area will be 
conﬁ  rmatory. It is for this reason that random 
biopsy samples were not taken of clinically normal 
skin in our patients. We were unable to perform a 
full excision of the lesion as the recruited patients 
were all by deﬁ  nition not suitable for surgery. We 
do appreciate that in the absence of histological 
conﬁ  rmations and the small numbers in the study 
the conclusions are softened.
LM recurrence following surgery is presumably 
the result of pre-existing amelanotic melanoma 
obscuring tumour margins and leading to incomplete 
excision. Thus imiquimod treatment of recurrent 
lesions must include a wide margin of apparently 
uninvolved skin around the recurrent lesion.
18 
Follow up should continue for each patient for 
5 years.
21
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